<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952846</url>
  </required_header>
  <id_info>
    <org_study_id>2016_ASWISPIC</org_study_id>
    <nct_id>NCT02952846</nct_id>
  </id_info>
  <brief_title>Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment</brief_title>
  <acronym>ASWISPIC</acronym>
  <official_title>Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective interventional study with three main aims:

        1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric
           intensive care patients.

        2. Test whether implementation of an algorithm for tapering of analgosedation changes the
           frequency and severity of withdrawal symptoms in the same population.

        3. Investigate how the health care providers experience having to adhere to such an
           algorithm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients &lt; 18 years of age treated in an intensive care unit for 5 days or more with infusion
      of opioids and/or benzodiazepines, are eligible for inclusion. Patients are included at the
      time tapering of these drugs is initiated. Part one of the study is observational. Drugs
      administered, complications, Comfort score and WAT-1 (Withdrawal Assessment Tool-1) score is
      recorded. Before part two of the study, an algorithm for tapering of analgosedation is
      implemented, and the data set is obtained as in part one.

      For part three of the study, focus group interviews will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean peak WAT-1 score</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time used tapering analgosedation</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU days</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug doses used</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort score</measure>
    <time_frame>Through study completion, up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Drug Withdrawal Symptoms</condition>
  <condition>Critical Care</condition>
  <condition>Child</condition>
  <arm_group>
    <arm_group_label>Before algorithm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algorithm for tapering of analgosedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Algorithm for tapering og analgosedation</intervention_name>
    <description>Algorithm for tapering og analgosedation</description>
    <arm_group_label>After algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; 18 years

          -  treated in PICU

          -  Infusion of opioids and/or benzodiazepins for 5 days or more.

        Exclusion Criteria:

          -  Neuromuscular disease

          -  Cognitive/neurological disturbance caused by a disease

          -  Multiple disabilities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar bentsen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunnar Bentsen, MD PhD</last_name>
    <phone>+47 23070000</phone>
    <email>gbentsen@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Even Fagermoen, MD PhD</last_name>
    <phone>+47 23070000</phone>
    <email>evefag@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0871</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Bentsen, MD PhD</last_name>
      <phone>+47 23073700</phone>
      <email>gbentsen@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Gunnar Bentsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Gunnar Bentsen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

